Chikungunya Virus Vaccine

About Auro Vaccines

Auro Vaccines, a wholly-owned subsidiary of Aurobindo Pharma USA, is a clinical-stage biotech focused on a fundamental new approach to vaccine design. Its proprietary PBS Vax™ platform allows precise 'tuning' of immune responses to overcome the shortcomings of current DNA and classic prophylactic vaccines. The company has established a pipeline targeting high-unmet-need areas like HPV-associated cervical dysplasia, SARS-CoV-2, Chikungunya, and RSV, and maintains significant partnerships with entities like Emergent BioSolutions and CEPI for filovirus and other outbreak pathogen vaccines.

About Phylex BioSciences

Phylex BioSciences is a private, pre-clinical stage biotech leveraging advanced AI and deep learning to design next-generation mRNA nanoparticle vaccines. Its core technology platform aims to overcome limitations of current vaccines, such as immune imprinting and short-lived immunity, by encoding for highly immunogenic nanoparticles. The company's pipeline targets high-fatality and emerging viruses like Nipah, SARS-CoV-2, Chikungunya, West Nile, and human metapneumovirus, positioning it in the growing field of proactive pandemic preparedness.

Therapeutic Areas